Thursday, May 12, 2022
PDS Biotechnology Corp (PDSB)
Clinical Progress Continues As 1Q22 Results Were Within Expectations
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.
Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
PDS Biotechnology Reported 1Q22. PDS Biotechnology reported a loss of $8.5 million or $(0.32) per share for 1Q22, consistent with our expectations. The company also gave updates on its clinical trials and pipeline products, and has two upcoming poster presentations scheduled to provide clinical data updates from PDS0101 trials in trials for HPV-associated cancers. Cash on hand at the end of the quarter was $58.9 million.
PDS0101 Has Four Trials For HPV-Associated Cancer. The lead product is PDS0101, a cancer therapy that uses the Versamune technology to deliver the HPV16 antigen. There are four trials in progress that test the drug in HPV-associated cancers found in any tissue or location, and at different stages of disease, and in combination with other drugs. Two clinical updates are scheduled for the American Society of Clinical Oncology (ASCO) from June 3-7….
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
